

We claim:

1. Use of an alpha2-adrenoceptor antagonist in the manufacture of a medicament for inhibiting the development of epilepsy in a patient at risk of developing epilepsy.
2. The use according to claim 1, wherein the alpha2-adrenoceptor antagonist is atipamezole or a pharmaceutically acceptable salt thereof.
3. The use according to claim 1, wherein the alpha2-adrenoceptor antagonist is idazoxan or a pharmaceutically acceptable salt thereof.
4. The use according to claim 1, wherein the alpha2-adrenoceptor antagonist is efaroxan or a pharmaceutically acceptable salt thereof.
5. The use according to claim 1, wherein the alpha2-adrenoceptor antagonist is 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole or a pharmaceutically acceptable salt thereof.
6. The use according to claim 1, wherein the alpha2-adrenoceptor antagonist is an analog chosen from analogs of atipamezole, analogs of idazoxan, and analogs of efaroxan.
7. The use according to claim 1, wherein said risk of developing epilepsy is caused by head trauma, brain ischemia, infection or neurosurgical operation.